Published: 12:00 CET 31-12-2015 /GlobeNewswire /Source: FIT Biotech Oy / : FITBIO /ISIN: FI4000148606
Company Release December 31, 2015 at 13:00 hrs EET
FIT Biotech's long time CEO retires
The Finnish biotechnology company FIT Biotech's (NASDAQ: FITBIO) long time CEO, Dr. Kalevi Reijonen, (68) will retire as per 1.1.2016. He will continue in the Company as the Chief Medical Officer (CMO).
The recruitment process of the new CEO is in progress. The acting CEO is the Chairman of the Board Mr Rabbe Slätis until the new CEO is appointed.
"We thank Kalevi for his contribution in taking FIT Biotech into a stage where it is good for the new CEO to follow. Since 2003 Kalevi has been building FIT Biotech into international biotechnology company and successfully listed it on Nasdaq Helsinki's First North Finland marketplace", states FIT Biotech's Chairman of the Board Rabbe Slätis.
FIT BIOTECH OY
Board of Directors
Chairman of the Board, FIT Biotech Oy
Tel: +358 (0) 40 840 6749
Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790
FIT Biotech Oy in brief:
FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA vaccines and gene therapy. The company bases its products on its patented GTU ® (Gene Transport Unit) technology.
Through GTU technology, FIT Biotech develops DNA vaccines in order to both prevent and also treat various diseases. Identified application areas include HIV, tuberculosis (and other infectious diseases) as well as gene therapy (cancer, autoimmune diseases). Other application areas are under development.
FIT Biotech Oy is listed on NASDAQ First North (ticker: FITBIO). More information can be found at www.fitbiotech.com.
NASDAQ OMX Helsinki
This announcement is distributed by NASDAQ OMX Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: FIT Biotech Oy, Biokatu 8, Tampere FI-33520, Finland
If you would like to unsubscribe and stop receiving these e-mails click here.